Pancreatic acinar cell carcinoma
MONDO:0006346An adenocarcinoma arising from the pancreas. It is characterized by the presence of relatively uniform malignant cells which form acinar patterns. It usually occurs during adulthood. Signs and symptoms include abdominal pain, weight loss, nausea, and diarrhea. It may metastasize to regional lymph nodes and the liver. A minority of patients develop lipase hypersecretion syndrome. This syndrome may be seen in patients with liver metastases and it is characterized by excessive secretion of lipase in the serum, polyarthralgia, and subcutaneous fat necrosis.
Also known as: Pancreatic acinar cell cancer, acinar cell adenocarcinoma of pancreas, acinar cell adenocarcinoma of the pancreas, acinar cell carcinoma of pancreas, acinar cell carcinoma of the pancreas, carcinoma of pancreatic acinar cell, pancreas acinar cell adenocarcinoma, pancreatic acinar cell adenocarcinoma
2895 clinical trials for this condition and its sub-types, 12 tagged with Pancreatic acinar cell carcinoma itself.
Follow this condition to get notified about new trialsWhere it sits in the disease tree
Browse by category →Sub-types of Pancreatic acinar cell carcinoma
-
Experimental drug cocktail targets Hard-to-Treat cancers
Disease control OngoingThis early-phase study tests a combination of two targeted drugs (vismodegib and erlotinib) with or without a standard chemotherapy drug (gemcitabine) in people with advanced pancreatic cancer or other solid tumors that cannot be removed by surgery. The main goal is to find the s…
Phase 1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Sep 10, 2026 00:00 UTC
-
Immunotherapy duo takes on rare tumors
Disease control OngoingThis phase 2 trial is testing a combination of two immunotherapy drugs, nivolumab and ipilimumab, in 798 people with over 50 types of rare cancers. The goal is to see if these drugs can shrink tumors by helping the immune system attack cancer cells. Participants receive the drugs…
Phase 2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
Experimental vaccine targets Hard-to-Treat pancreatic cancer
Disease control OngoingThis early-phase study tested a vaccine therapy given directly into the tumor along with a growth factor to boost the immune system in 18 people with advanced pancreatic cancer that could not be removed by surgery. The main goal was to find the safest dose and check for side effe…
Phase 1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jun 27, 2026 12:23 UTC
-
New drug cocktail aims to stall deadly pancreatic cancer
Disease control OngoingThis study tests whether combining two drugs, pembrolizumab and olaparib, can help people with a specific type of advanced pancreatic cancer keep their disease from growing. The trial includes 63 adults whose cancer has a genetic flaw called HRD or has responded well to platinum …
Phase 2 • Sponsor: Memorial Sloan Kettering Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 09:05 UTC
-
New hope for BRCA pancreatic cancer? trial tests adding cisplatin to standard chemo
Disease control OngoingThis phase II/III trial compares a three-drug chemotherapy combination (nab-paclitaxel, gemcitabine, plus cisplatin) against the standard two-drug combo (nab-paclitaxel plus gemcitabine) in people with metastatic pancreatic cancer that has BRCA1, BRCA2, or PALB2 gene mutations. T…
Phase 2/3 • Sponsor: Alliance for Clinical Trials in Oncology • Aim: Disease control
Last updated Jun 27, 2026 08:08 UTC